Catarina Silva, MSc,  —

The U.S. Food and Drug Administration (FDA) has agreed to review a request to approve Trevyent (treprostinil) as a treatment of pulmonary arterial hypertension (PAH), United Therapeutics announced in a press release. An FDA decision on this updated New Drug Application (NDA) for Trevyent is expected on or before…

Development of pulmonary hypertension (PH) in cystic fibrosis (CF) patients compromises lung function and blood-gas parameters, but does not significantly worsen survival, an analysis suggests. The study, “Prognostic significance of pulmonary hypertension in patients with cystic fibrosis: A systematic review and meta-analysis,” was published in the journal …